Werfen (formerly Immucor, Inc.)

Werfen (formerly Immucor, Inc.) is a global leader in specialized diagnostics for transfusion and transplantation medicine. The company manufactures a comprehensive portfolio of serology-based reagents, automated instruments, and molecular diagnostic products serving blood banks, transfusion services, clinical laboratories, reference laboratories, donor centers, and transplant programs worldwide. Core product lines include: (1) Transfusion diagnostics—blood typing, antibody screening and identification, platelet serology, and HLA donor screening assays; (2) Transplant diagnostics—HLA typing kits (including NanoTYPE® HLA-11 Plus), HLA and non-HLA antibody detection products, and post-transplant monitoring assays; and (3) Coagulation diagnostics for heparin-induced thrombocytopenia (HIT) and thrombotic thrombocytopenic purpura (TTP) detection. Signature automated platforms include the NEO® and NEO Iris® systems for immunohematology automation, and Echo Lumena® for antibody identification with enhanced imaging. The company acquired Omixon (Hungary) to expand HLA typing capabilities. Werfen operates globally across hospital blood banks, reference laboratories, and transplant centers, leveraging customer-centric support with field representatives who possess transfusion and transplant technical expertise. The company emphasizes regulatory compliance, quality assurance, and comprehensive technical and educational support to streamline laboratory workflows and improve patient outcomes in transfusion and transplant medicine.